A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

Inclusion Criteria: * Histologically or cytologically confirmed esophageal squamous carcinoma * 18≤age≤75 * ECOG PS is 0-1 * TanyN+M0 or T3-4NanyM0 tumors * Patients must have surgically resectable disease treatable by esophagectomy, as assessed by a thoracic surgeon * No prior chemotherapy,radiotherapy and immunotherapy * Disease must be clinically limited to the esophagus * No esophageal perforation and no active esophageal bleeding * No interstitial pneumonia or history of interstitial pneumonia * FEV1\>1.2L * Adequate organ function defined at baseline as: WBC ≥3,000/ L，ANC ≥1,500/ L，Platelets ≥100,000/ L，Hb ≥9 g/dl； Calculated creatinine clearance \>40 ml/min using Cockcroft-Gault method: Males: Creatinine CL = Weight (kg) x (140 - Age) . (mL/min) 72 x serum creatinine (mg/dL)Female：Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg/dL)；Total serum bilirubin ≤1.5 mg/dL， AST/ALT ≤2.5× upper limit of normal，Mean QT interval corrected for heart rate (QTc) \<470 ms calculated from 3 ECGs using Frediricia's Correction * Able to provide written informed consent * Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up Exclusion Criteria: * Previous treatment with chemotherapy, radiotherapy or immunotherapy * Cervical esophageal cancer * Esophageal perforation or active esophageal bleeding * Interstitial pneumonia or history of interstitial pneumonia * Patients with evidence of metastatic disease * Chronic Hepatitis B or C infection (e.g. Hepatitis B surface Ag positive or detectable viral load for Hepatitis B or C). Patients with prior evidence of Hepatitis B or C without active infection are eligible * Autoimmune diseases (such as systemic lupus erythematosus, rheumatoid rthritis, inflammatory bowel disease, autoimmune thyroid disease), but allow the following diseases to enter the next stage of screening: type I diabetes, skin diseases without systemic treatment (such as vitiligo, psoriasis) * 14 days before the first dose, the patient had an active infection that required systemic treatment * Inability to understand or may not comply with test requirements